IOL Chemicals and Pharmaceuticals Limited held its earnings conference call on February 12, 2026, following the submission of Q3 and nine-month FY26 financial results to stock exchanges. The call was moderated by MUFG Investor Relations and featured key management personnel including CFO Pardeep Kumar Khanna, Senior VP Abhay Raj Singh, Director Works Kushal Kumar Rana, and Advisor Rakesh Mahajan.

Q3 FY26 Financial Performance

The company reported strong operational performance for the third quarter. Revenue from operations reached ₹580.40 crore, representing 10.90% year-on-year growth from ₹523.30 crore in Q3 FY25. EBITDA improved significantly to ₹62.60 crore with a margin of 10.70%, marking 22.80% year-on-year growth from ₹50.90 crore.

Nine-Month FY26 Consolidated Results

For the nine-month period ended December 2025, the company demonstrated robust growth across key financial metrics. Revenue from operations grew 9.60% to ₹1,699.60 crore from ₹1,551.40 crore in the previous year. EBITDA surged 24.80% to ₹196.10 crore from ₹157.10 crore, with an improved margin of 11.40% compared to 10.00% in the previous year.

Segment-wise Performance Analysis

The pharmaceuticals segment continued its strong performance with revenue of ₹356.10 crore in Q3 FY26, representing 61% of total revenue. The chemicals segment contributed ₹224.30 crore, accounting for 39% of total revenue. Within the pharmaceutical segment, ibuprofen contributed ₹228.00 crore while non-ibuprofen products generated ₹128.00 crore, with non-ibuprofen now representing 36% of pharmaceutical revenue compared to 34% in the previous year.

Capacity Utilization and Operational Highlights

Management reported strong capacity utilization across business segments. The ibuprofen plant operates at 90-95% capacity utilization, while the ethyl acetate plant runs at nearly 100% capacity. For pharmaceuticals, the company utilizes over 90% capacity except for paracetamol, where capacity expansion is ongoing. The company's paracetamol capacity has been expanded to 10,800 MTPA through the new Unit 11.

Strategic Developments and Future Outlook

The company declared an interim dividend of 50% per equity share for FY26, reflecting confidence in performance and outlook. Management highlighted the strategic shift towards high-value APIs, with non-ibuprofen products contributing 34% of pharmaceutical segment revenue. The company recently received CEP certification for minoxidil and expects to commence commercial production in Q1 FY27.

For FY27, management expects minimum 10-15% growth in top line and 15-20% growth in bottom line, with planned capex of ₹150-200 crore. The company targets achieving ₹2,700 crore total revenue by FY27, with ₹1,800 crore from API business and ₹900 crore from chemicals business.

IOL Chemicals & Pharmaceuticals Limited announced its unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025, through a regulatory filing on February 11, 2026. The Board of Directors approved the results at their meeting held on the same day, which commenced at 1:15 PM and concluded at 2:31 PM.

Q3 FY26 Financial Performance

The company reported steady financial performance for the quarter ended December 31, 2025. The standalone financial results showed consistent operational metrics across key parameters.

Nine Months Performance

For the nine months period ended December 31, 2025, the company demonstrated strong growth momentum across all key financial parameters.

Segment-wise Performance

The company operates through two primary segments - Pharmaceuticals and Chemicals. For Q3 FY26, the pharmaceutical segment generated revenue of ₹356.05 crore compared to ₹300.58 crore in Q3 FY25, while the chemical segment recorded ₹287.82 crore against ₹275.14 crore in the corresponding previous quarter.

Interim Dividend Declaration

The Board of Directors declared an interim dividend of ₹1 per equity share (50%) having face value of ₹2 each for the financial year 2025-26. The company has fixed February 17, 2026 as the record date to determine eligible shareholders for the interim dividend payment.

Exceptional Items and Corporate Developments

The company reported exceptional items worth ₹11.21 crore in Q3 FY26, primarily arising from changes in wage definition following the notification of four Labour Codes by the Government of India on November 21, 2025. During the quarter, the Board approved the closure of IOL Life Sciences Limited, a wholly owned subsidiary, through striking off from the Register of Companies. Additionally, the company incorporated IOL Pharmaxis UK Limited in the United Kingdom on October 16, 2025, though business operations have not yet commenced.

Auditor Certification

The financial results received an unmodified review report from statutory auditors Ashwani & Associates, Chartered Accountants. The results were prepared in accordance with Indian Accounting Standards (Ind AS) and comply with SEBI listing regulations. The company confirmed that both standalone and consolidated results are available on its website at www.iolcp.com .